

ASSOCIATION OF  
NORTHERN CALIFORNIA ONCOLOGISTS  
&  
AMERICAN SOCIETY OF CLINICAL ONCOLOGY  
*invite oncologists, oncology nurses, oncology practice administrators, and their guests to*  
**THE STATE OF CANCER CARE**

*with*

**Margaret Tempero, M.D.**

*Director, Pancreas Center & Leader, Pancreas Cancer Program  
Rombauer Family Distinguished Professor in Pancreas Cancer Clinical and Translational Science  
Professor of Medicine  
University of California, San Francisco  
Editor-in-Chief, Journal of the National Comprehensive Cancer Network*

*&*

**Wes Kidder, M.D.**

*Clinical Fellow, University of California, San Francisco*

**Summary**

Drs. Tempero and Kidder will present and discuss their perspectives on the state of clinical oncology care based on findings presented at ASCO's 2017 Annual Meeting.

*This talk is scheduled for:*

**THURSDAY, June 15<sup>th</sup>, 2017**

**6:00PM Registration, Reception, & Exhibits**

**7:00PM Dinner • 8:00PM Talk**

***San Francisco Marriott Marquis • 780 Mission Street • San Francisco  
(415) 896-1600***

*Please call the meeting location for directions.*

FAX your reservation(s) to José Luis González, *ANCO Executive Director*, at (415) 472-3961 no later than Friday, June 9<sup>th</sup>.

**This event is being held the evening before ASCO's *Best of ASCO San Francisco Meeting*. Registration for *Best of ASCO* does not include registration for this program and attendance is limited. FAX this program registration to ANCO to register; visit [boa.asco.org](http://boa.asco.org) to register for *Best of ASCO*.**

***ANCO's The State of Cancer Care is not an official event of the 2017 Best of ASCO San Francisco Meeting. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation. Not-CME-accredited.***

Support for this meeting is provided by ANCO's Sustaining Level Corporate Members *Astellas Oncology, Celgene, Incyte, Taiho Oncology, Takeda Oncology, and Teva Oncology*. Additional support is anticipated from *AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Eisai, Exelixis, Genentech BioOncology, Genomic Health, Merck, Pfizer Oncology, Seattle Genetics, and Tesaro Oncology*. A complete list of supporters will be available at the meeting. Industry representatives from non-supporting companies will be charged a \$100 registration fee to attend.

I/We will attend *The State of Cancer Care* (please print clearly):

Name(s): \_\_\_\_\_ e-mail: \_\_\_\_\_